IPM Brief – Issue 21 | The Patient Is Downstream. Power Got There First

Greetings, all!

August is for holidays. Power does not take them.

Another International Personalised Medicine Alliance dispatch from your personalised medicine friends , and August has refused to behave like August.

Italy’s Parmesan is sweating through a heatwave, while Brussels is discovering that its cybersecurity rules may classify ice-cream makers as critical infrastructure. At this rate, Europe’s resilience strategy will depend on keeping the gelato frozen and the Parmigiano properly aged.

Across the Atlantic, Vice President JD Vance wants the US Justice Department to investigate providers of gender-affirming care bringing federal prosecutorial power directly into an already contested area of medicine.

In Europe, governments are deciding what counts as critical. In America, who counts as a suspect.

The contrast may be surreal. The underlying question is not: Who gets to decide?

Then there is Neena Nizar.

Nizar lives with Jansen’s disease, an extraordinarily rare genetic disorder that also affects her two sons. Faced with a condition too rare to attract a conventional research programme, she did not wait for the system to find her. She built a foundation, connected patients with scientists, helped drive the research forward and became the first participant in a clinical trial she had helped make possible.

Most patients encounter medicine downstream. Nizar fought her way upstream.

Her story sits alongside a first-of-its-kind narcolepsy drug that targets the biology of the disorder rather than merely suppressing its symptoms; a blood test detecting lesions before they become cancer; a possible $400 billion pharmaceutical merger; half a trillion dollars moving into American manufacturing; treatments reaching the market while crucial evidence remains unfinished; and Ebola accelerating through a health system under attack.

These stories look unrelated. They are not.

The common thread is not technology. It is power—and who gets to exercise it before the patient enters the room.

A board decides who owns the medicine. A government decides where it will be made. A pricing rule shapes whether it will be launched. A regulator determines how much uncertainty patients must absorb. A laboratory threshold decides who qualifies for testing. A prosecutor may influence which care a doctor is willing to provide. In a conflict zone, somebody may already have decided that the hospital itself is a target.

Personalised medicine is moving upstream: from treating symptoms to correcting biology, from late diagnosis to early detection, from intervention to prevention. That can be revolutionary. But power is moving upstream too—and faster than accountability.

Nizar’s story shows what becomes possible when patients move upstream with it.

This Brief follows that power from the boardroom to the laboratory, from Washington to Switzerland, from scientific breakthroughs to regulatory shortcuts, from healthcare exclusion to federal investigation, and from Congo’s Ebola treatment centres to hospitals under fire.

The political test is brutally simple: Who benefits from the decision? Who carries the uncertainty? And who was missing from the room?

In this issue

• The $400 Billion Merger Story Nobody Could Explain: AstraZeneca and Bristol Myers Squibb discussed, denied and never publicly explained a potentially historic combination.
• Washington Just Moved Half a Trillion Dollars: Tariff pressure is pulling pharmaceutical factories, research investment and political leverage into the United States.
• America’s Drug-Price War Has Crossed the Atlantic: Companies may be delaying Swiss reimbursement applications to protect their American prices.
• The Blood Test That Wants to Beat Cancer to the Door: A new test detected both colorectal cancer and the lesions that can become cancer.
• The Drug Has a Price. Survival Is Still Pending: The FDA approved a $29,500 treatment cycle before its confirmatory survival evidence matured.
• AstraZeneca’s $80 Billion Target Has Met Biology: Another late-stage failure exposes the collision between scientific uncertainty and corporate promises.
• Generics Were the Escape Hatch. Now Price-Fixing Is on Trial: Allegations of collusion threaten the market supposed to protect patients from monopoly prices.
• Washington Is Using Medicaid to Police Medicine: Federal funding for gender-affirming care is being withdrawn from low-income children and families.
• Ebola Is Finding Patients After They Die: Congo’s deadliest Ebola outbreak is exposing the fatal price of delayed diagnosis.
• Four Attacks a Day. Zero Accountability: Healthcare facilities, workers and patients are being attacked while the international response stops at counting.

This is not another health news digest. It’s a twice-weekly readout of where evidence meets power and where power must turn into action.

---

The $400 Billion Merger Story Nobody Could Explain

Reuters reported that AstraZeneca and Bristol Myers Squibb had held preliminary discussions about a combination worth nearly $400 billion. AstraZeneca’s shares fell around 9% as investors questioned the strategic logic, patent exposure and overlap between the companies’ oncology portfolios. Days later, a senior source told Reuters there had never been a deal to complete and that no discussions were taking place. Neither company publicly explained what had happened. (Reuters: preliminary discussions; Reuters: subsequent denial)

Whether the talks were preliminary, advanced or never commercially serious, the market’s reaction exposed the weakness of the mega-merger model. Scale is not a patient strategy. If a transaction cannot demonstrate faster trials, stronger evidence, wider access or lower costs, it is not healthcare transformation. It is balance-sheet anxiety wearing a science logo.

---

Washington Just Moved Half a Trillion Dollars

Global drugmakers have announced more than $500 billion in US manufacturing, research and supply-chain commitments amid tariff threats and political pressure to reduce dependence on overseas production. Pfizer has pledged $70 billion, Johnson & Johnson $55 billion, Roche and AstraZeneca more than $50 billion each, and Novartis $23 billion across ten new or expanded sites. (Source: Reuters)

This is not the invisible hand of the market. It is industrial policy delivered with a tariff notice. America is using access to the world’s most profitable medicines market to decide where future factories, laboratories and skilled jobs will sit. Europe should be alarmed. A continent that regulates innovation but loses the capacity to develop and manufacture it risks becoming a customer of its own scientific legacy.

---

America’s Drug-Price War Has Crossed the Atlantic

Around one-third of recently developed innovative medicines were not submitted for Swiss reimbursement between January 2025 and June 2026, according to an analysis by the industry association Interpharma. Only 15 reimbursement applications were filed, compared with an average of 24 in comparable periods. The association argues that companies fear lower Swiss prices could be imported into the United States through America’s most-favoured-nation pricing policy. (Source: Reuters)

Interpharma represents the industry, so its explanation is interested evidence rather than neutral truth. But the access warning is real. If securing a lower price in Bern threatens revenue in Washington, companies gain an incentive to delay the Swiss launch. Badly designed international price linking does not end the fight over prices. It moves the waiting list across a border and turns patients into negotiating collateral

---

The Blood Test That Wants to Beat Cancer to the Door

An experimental blood test evaluated in more than 1,500 adults in China, Japan and Spain detected 92% of stage I to III colorectal cancers and 81% of advanced adenomas, the precancerous lesions that can be removed before cancer develops. The test achieved 85% specificity, although it performed less effectively against flat lesions. A positive result would still require a colonoscopy. (Source: Reuters, reporting research in The Lancet Gastroenterology & Hepatology)

This is where moving upstream can genuinely serve patients. The test should not be sold as a replacement for colonoscopy. Its value lies in identifying who needs colonoscopy first and bringing reluctant populations into screening. But a blood draw changes nothing if the patient then waits months for confirmation. Without workforce, referral and endoscopy capacity, innovation will not eliminate the queue. It will simply make the queue more precise.

---

The Drug Has a Price. Survival Is Still Pending.

The FDA granted accelerated approval to Bristol Myers Squibb’s Zenbexus, or iberdomide, with daratumumab and dexamethasone for relapsed or refractory multiple myeloma. The decision was based on improvements in minimal residual disease while the Phase III trial continues to assess progression-free survival. The treatment carries a boxed embryo-foetal toxicity warning and a US list price of $29,500 for each 28-day cycle. (Source: Reuters; FDA guidance on minimal residual disease endpoints)

Accelerated approval can be justified when patients face serious disease and limited options. But it creates a debt to the public. The clinical benefit remains provisional while the commercial price becomes certain on day one. At $29,500 every four weeks, the confirmatory trial cannot become an administrative footnote. Approval must carry enforceable deadlines, transparent results and a credible route to withdrawal if meaningful benefit fails to materialise.

---

AstraZeneca’s $80 Billion Target Has Met Biology

AstraZeneca has discontinued a Phase III trial of volrustomig with chemotherapy in metastatic non-small cell lung cancer after an independent committee concluded that the combination was unlikely to improve progression-free or overall survival in patients whose tumours lacked PD-L1. Other trials of volrustomig will continue, and separate studies involving Tagrisso with Orpathys and Enhertu produced positive results. AstraZeneca continues to target $80 billion in annual revenue by 2030, supported by as many as 20 new medicine launches. (Source: Reuters)

Biology does not negotiate with revenue guidance. A failed trial is not a scandal. It is how science eliminates weak hypotheses before they reach more patients. The political danger begins when enormous sales promises turn experimental medicines into financial obligations. When every molecule is required to support a corporate target, stopping a failing programme becomes an investor crisis rather than evidence that the system worked.

---

Generics Were the Escape Hatch. Now Price-Fixing Is on Trial.

Humana has agreed not to identify Teva as an Israeli company during an upcoming US trial after Teva argued that the Gaza war could prejudice jurors. Humana alleges that Teva and other manufacturers conspired to inflate prices for generic medicines including baclofen and propranolol. Teva denies the allegations. Separately, Sandoz recently agreed to a $450 million settlement with 43 US states and territories over antitrust claims, without admitting wrongdoing. (Reuters: Humana and Teva; Reuters: Sandoz settlement)

The dispute over Teva’s nationality is politically combustible, but it must not bury the central allegation. Generics are the health system’s escape hatch from monopoly pricing only when manufacturers genuinely compete. The court must determine whether the allegations are proven. Policymakers must determine why a market designed to deliver affordable medicines remains vulnerable to repeated accusations that the competition is theatre.

---

Washington Is Using Medicaid to Police Medicine

The Trump administration has finalised a rule barring federal Medicaid and Children’s Health Insurance Program funding for puberty blockers, hormone therapies and gender-affirming surgery for minors. The measure takes effect on 13 October 2026, with limited transitional coverage for current patients. The administration argues that the evidence of benefit is insufficient and the risks are too high. Major medical organisations oppose the decision, while legal challenges are expected. Medicaid and CHIP together cover around 35.5 million children. (Source: Reuters)

This is not simply a clinical guideline. It is federal benefit design being used to impose a contested medical judgement on low-income families. Wealthier families may retain private options. Poorer families will carry the prohibition. If the evidence is disputed, the answer should be rigorous eligibility criteria, specialist oversight and long-term follow-up. Poverty should not become the mechanism through which Washington settles an ideological argument.

---

Ebola Is Finding Patients After They Die

Congo’s Ebola outbreak has killed 2,325 people among 4,945 confirmed cases, making it the deadliest outbreak in the country’s history. The epidemic is caused by the Bundibugyo species, for which there is no approved vaccine or treatment. Its reported fatality rate rose from around 20% in early June to 46% by mid-August. Experts say the increase points principally to late detection, weak surveillance and limited access to care, with some infections identified only after the patient has died. (Source: Reuters)

Personalised medicine begins with finding the right person at the right time. Congo is struggling to find people while treatment can still help them. At that point, genomic platforms and experimental vaccines cannot compensate for surveillance that arrives after the funeral. Laboratories, trusted local health workers, safe transport and rapid contact tracing are not supporting infrastructure. In an outbreak, they are the treatment pathway.

---

Four Attacks a Day. Zero Accountability.

More than 900 attacks on healthcare were recorded in conflict zones between January and August, killing at least 900 people and injuring more than 1,400, according to WHO data. All 36 hospitals in Gaza have been damaged, while only around half remain partly operational. In Sudan, 37% of health facilities are non-functional. Since WHO began monitoring these incidents in 2018, it has verified more than 10,400 attacks. The agency says none has entered an accountability process. (Source: Reuters)

An attack on healthcare does not end when the explosion stops. It continues through every cancelled operation, missed diagnosis, interrupted vaccination and ambulance that cannot make the next journey. Verification without prosecution is becoming an archive of impunity. Governments cannot celebrate precision medicine in conference halls while accepting the destruction of hospitals as a normal instrument of war.

---

The August Watch

Registrations are now open for our events in New York (September 24), Stockholm (September 12) and Dublin (October 2).

Visit our Events page to explore what’s coming up and reserve your place.

---

Follow the last-mile conversation!

IPM Alliance tracks the decisions, bottlenecks and implementation gaps shaping personalised medicine access. Follow us for briefings, events, policy signals and practical insights from across regions and disease areas.

• LinkedIn
• YouTube
• X

---

We want to hear from you

When a patient becomes eligible for personalised care, where does the system most often lose them: identification, testing, referral, reimbursement, delivery capacity or equity?

---

Know someone who should be reading this?

IPM Brief is built for people working where science, policy and patient access collide. If one colleague would find this useful, forward it to them and help bring them into the conversation.

---

International Alliance for Personalised Medicine

Avenue de l’Armée / Legerlaan 10, 1041 Brussels, Belgium